Companion Diagnostics Oncology Market at USD 5.11 billion in 2026 and USD 5.70 billion in 2027. Revenue is forecast to reach USD 12.3 billion by 2034, representing an 11.61% CAGR during 2026–2034. The report examines market segments, regional demand, technology developments and company positioning.

 Full report: https://www.oganalysis.com/industry-reports/companion-diagnostics-oncology-market

Market Overview: Biomarker Testing for Precision Cancer Treatment

Companion diagnostics connect laboratory findings with the selection of a corresponding cancer therapy. Assays examine tumor tissue or blood samples for molecular features that help establish treatment eligibility. Their value depends on reliable results that clinicians can interpret within the approved treatment indication. Applications include targeted therapies and selected immunotherapies across solid tumors and blood cancers, with testing performed through hospital pathology services and specialist laboratories.

Broader sequencing panels and blood-based testing are extending the information available for treatment decisions. Drug developers and diagnostic suppliers are coordinating assay development with clinical programs and regulatory submissions. These developments create opportunities for suppliers that combine validated tests with practical laboratory workflows. Adoption also depends on reimbursement, suitable samples and access to therapies matched to test results. Detecting a biomarker alone does not guarantee that a treatment will be available or effective.

Key Market Insights: Market Size, Segment Leadership and Demand Trends

•  Revenue is projected to rise from USD 5.11 billion in 2026 to USD 12.3 billion in 2034, at an 11.61% CAGR.

•  Test Kits account for an estimated 69% share in 2026, the largest product category in the report.

•  Lung Cancer leads applications with an estimated 34% share in 2026, reflecting the importance of molecular testing in therapy selection.

•  Hospitals represent the largest end-user category, with an estimated 52% share in 2026.

•  NGS panels and liquid biopsy offer opportunities to assess more biomarkers and support testing when tumor tissue is difficult to obtain.

•  North America holds 41% of the 2026 market. The report identifies Europe as the fastest-growing region.

Market Dynamics: Drivers, Restraints and Market Growth Opportunities

•  Driver: Therapy labels that require biomarker confirmation make accurate diagnostic testing an essential part of treatment eligibility assessment.

•  Driver: New companion diagnostic indications extend the use of established platforms to additional therapies, biomarkers and cancer types.

•  Opportunity: Multiplex sequencing can assess multiple molecular alterations within one workflow, supporting more comprehensive tumor characterization.

•  Opportunity: Blood-based assays offer an additional testing route when a tissue biopsy is impractical or the available specimen is insufficient.

•  Restraint: Variable coverage and reimbursement can limit access to molecular testing, particularly where clinical evidence does not satisfy payer requirements.

•  Restraint: Limited tissue, tumor heterogeneity and assay detection limits can complicate interpretation; some negative plasma results require follow-up tissue testing.

•  Opportunity: Diagnostic and pharmaceutical partnerships can align trial testing, assay validation and regulatory submissions with potential therapy launches.

Browse for More Information

https://www.oganalysis.com/industry-reports/companion-diagnostics-oncology-market

Market Segmentation: Products, Applications, End Users, Technologies and Channels

Product coverage comprises Test Kits, Software and Biomarkers. Applications include Lung Cancer, Breast Cancer, Colorectal Cancer and Hematologic Malignancies. The end-user analysis covers Hospitals, Research Institutes and Diagnostic Laboratories.

Technology coverage includes polymerase chain reaction (PCR), next-generation sequencing (NGS) and immunohistochemistry (IHC). Distribution channels comprise Direct Sales, Distributors and E-commerce. These dimensions distinguish the assay offering, clinical application, customer setting and route to market.

Regional Insights: Diagnostic Access and Commercial Priorities

•  North America: The report places the region first by revenue. For suppliers, coverage eligibility and integration with oncology treatment pathways remain key commercial considerations.

•  Europe: Identified as the fastest-growing region, Europe presents opportunities for broader testing access; country-specific reimbursement and implementation requirements shape commercialization.

•  Asia-Pacific: The country coverage includes China, India, Japan and Australia. Commercial priorities include affordable testing, laboratory capability and access to relevant therapies.

•  Middle East & Africa: Opportunities depend on connecting specialist laboratories with oncology services and improving access to validated tests and matched treatments.

•  South & Central America: Wider adoption will depend on testing affordability, dependable sample referral and reimbursement arrangements that support clinical use.

Competitive Landscape: Assay Platforms and Pharmaceutical Partnerships

The competitive field spans tissue diagnostics, genomic profiling and liquid biopsy. Recent approvals show suppliers extending existing platforms to additional treatment indications, while partnerships support prospective diagnostic development alongside drug pipelines. This suggests that commercial differentiation depends on the strength of clinical evidence and approved indications as well as assay coverage. Laboratory usability and access to reimbursement also influence whether a technically capable test becomes part of routine care.

Companies covered include Abbott Laboratories, Agilent Technologies, ARUP Laboratories, bioMérieux, Danaher Corporation, EntroGen, Eurofins Scientific, Exact Sciences, Foundation Medicine (Roche Group), Guardant Health, Illumina, Leica Biosystems, Myriad Genetics, Natera, QIAGEN, F. Hoffmann-La Roche and Thermo Fisher Scientific.

Recent Developments

•  September 2026: Guardant Health announced FDA approval of Guardant360 CDx for ESR1 mutation testing to guide camizestrant use in eligible patients with advanced breast cancer. Source

•  August 2026: FDA expanded Illumina TruSight Oncology Comprehensive indications to detect RET fusions in thyroid cancer and RET mutations in medullary thyroid cancer for selpercatinib selection. Source

•  June 2026: Guardant Health announced FDA approval of Guardant360 CDx to identify HER2 mutations linked to zongertinib eligibility in advanced non-small cell lung cancer. Source

•  May 2026: FDA approved FoundationOne CDx and FoundationOne Liquid CDx for identifying HRR gene alterations associated with talazoparib plus enzalutamide eligibility in metastatic castration-resistant prostate cancer. Source

•  May 2026: Guardant Health announced approval of Guardant360 Liquid CDx, expanding its genomic footprint and combining genomic and epigenomic information for blood-based tumor profiling. Source

•  April 2026: Guardant Health and Nuvalent partnered on trial testing and potential companion diagnostics, with commercialization subject to successful development and approvals. Source

•  March 2026: Myriad Genetics announced FDA approval of MyChoice CDx for assessing homologous recombination deficiency to identify eligible patients for niraparib treatment in advanced ovarian cancer. Source